18
Participants
Start Date
August 17, 2016
Primary Completion Date
February 10, 2018
Study Completion Date
March 17, 2026
Ibrutinib
Given PO
Laboratory Biomarker Analysis
Correlative studies
Pharmacogenomic Study
Correlative studies
Pharmacological Study
Correlative studies
University of Virginia Cancer Center, Charlottesville
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
Duke University Medical Center, Durham
Moffitt Cancer Center, Tampa
University of Kentucky/Markey Cancer Center, Lexington
Ohio State University Comprehensive Cancer Center, Columbus
Case Western Reserve University, Cleveland
University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Washington University School of Medicine, St Louis
UCHealth University of Colorado Hospital, Aurora
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
University of California Davis Comprehensive Cancer Center, Sacramento
National Cancer Institute (NCI)
NIH